Table 1 Characterstics of the study patients
From: Clinical significance of mTOR, ZEB1, ROCK1 expression in lung tissues of pulmonary fibrosis patients
Variables | N = 30 |
|---|---|
Age, years, median (range) | 57 (38-74) |
Male sex | 14 (46.7) |
Smoking | Â |
  Never smoker | 19 (63.3) |
  Former smoker | 7 (23.3) |
  Current smoker | 4 (13.3) |
Follow up, months | 40 (5-74) |
Connective tissue disease | 4 (13.3) |
Arterial blood gas analysis (n = 28) |  |
  pH | 7.41 ± 0.0 |
  PaO2, mmHg | 92.0 ± 16.0 |
  PaCO2, mmHg | 40.2 ± 4.0 |
  Saturation, % | 96.7 ± 1.7 |
White blood cell count | Â |
  Neutrophil, /mm3 | 4003 ± 1271 |
  Lymphocyte, /mm3 | 2327 ± 876 |
Bronchoalveolar lavage (n = 15) |  |
  Alveolar macrophage, % | 46.1 ± 21.1 |
  Neutrophil, % | 23.0 ± 22.2 |
  Lymphocyte, % | 17.5 ± 9.9 |
Pulmonary function test | Â |
  FVC, % | 75.3 ± 12.9 |
  FEV1, % | 86.9 ± 13.5 |
  DLCO, % | 65.0 ± 25.2 |
Radiologic features | Â |
  Ground glass opacities | 20 (66.7) |
  Reticular density | 10 (33.3) |
  Consolidation | 3 (10.0) |
  Traction bronchiectasis | 1 (3.3) |
  Honeycombing | 11 (36.7) |
Steroids or immunosuppressive treatment | 16 (53.3) |
Survivors | 24 (80.0) |